NRIX | tickerfilter.com

Fundamental analysis

35%

Profitability 18%

Dept financing 9%

Liquidity 75%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.44%

1 Month

-31.86%

3 Months

-49.23%

6 Months

-57.89%

1 Year

-47.03%

2 Year

3.70%

Key data

Stock price

$9.26

P/E Ratio

0.00

DAY RANGE

$8.80 - $10.39

EPS

-$2.36

52 WEEK RANGE

$8.60 - $29.56

52 WEEK CHANGE

-$40.98

MARKET CAP

1.566 B

YIELD

N/A

SHARES OUTSTANDING

64.412 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-14-2025

BETA

2.07

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,461,313

AVERAGE 30 VOLUME

$1,131,959

Company detail

CEO: Arthur T. Sands
Region: US
Website: nurixtx.com
Employees: 300
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy, is in Phase 1 clinical trials for gynecologic cancers, including ovarian, endometrial, and cervical cancer.

NRIX - Nurix Therapeutics, Inc.